Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
SOPHARMA AD hereby informs that from 29 July 2016 up to and including 1 August 2016 the Company bought 10 853 own shares representing 0.0081% of the share capital of the Company, at a total value of 29 813.99 BGN on the Bulgarian Stock Exchange, the average price per share was 2.75 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 463 774, representing 4.05% of the share capital of the Company.
SOPHARMA AD hereby informs that on 8 August 2016 the Company bought 450 own shares representing 0.00033% of the share capital of the Company, at a total value of 1242.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.76 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 468 688, representing 4.06% of the share capital of the Company.
In accordance with the provisions of art. 27, para 3 from Ordinance 2 on the prospectuses Sopharma AD hereby advises that the company has published and disseminated information to the public in the last 12 months in the Republic of Bulgaria and in other member states in the following ways:
1. Through the unified information system of the Bulgarian Stock Exchange E-register - www.fsc.bg;
